CRDF - Hot Stocks: BIIB Alzheimer's woes; CRDF CNTA clinical trial data; PRQR partnership deal; RKLB jumps on earnings

Biotech and drug development news dominated Thursday's midday action. This included Biogen (NASDAQ:BIIB), which dropped to a multi-month low after its CEO warned of slower-than-expected adoption of its controversial Alzheimer’s drug. Meanwhile, smaller players in the sector received significant buying interest amid a flurry of headlines. Cardiff Oncology (NASDAQ:CRDF) and Centessa Pharmaceuticals (NASDAQ:CNTA) rose following the release of clinical trial data. At the same time, ProQR Therapeutics (NASDAQ:PRQR) jumped more than 20% on news of a partnership with Eli Lilly (NYSE:LLY). Outside the world of biotech and drug development, Rocket Lab (NASDAQ:RKLB) posted a notable gain as well. The stock increased its value by nearly a third following the release of strong earnings figures. Speaking at an investor conference, Biogen (BIIB) CEO Michel Vounatsos said that only about 50 locations have administered at least one dose of its Alzheimer’s drug Aduhelm. This represented a slower rollout than expected, which Vounatsos attributed

For further details see:

Hot Stocks: BIIB Alzheimer’s woes; CRDF, CNTA clinical trial data; PRQR partnership deal; RKLB jumps on earnings